Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jupiter Neurosciences Inc (JUNS)

Jupiter Neurosciences Inc (JUNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,557
  • Shares Outstanding, K 34,426
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,440 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1000 +1.82%
on 12/12/25
1.3800 -18.84%
on 11/14/25
-0.2600 (-18.84%)
since 11/12/25
3-Month
1.1000 +1.82%
on 12/12/25
1.8395 -39.11%
on 09/30/25
-0.4000 (-26.32%)
since 09/12/25
52-Week
0.5100 +119.61%
on 04/14/25
19.5100 -94.26%
on 12/19/24
-14.2500 (-92.71%)
since 12/12/24

Most Recent Stories

More News
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum

Company advances JOTROL ™ into Phase 2a Parkinson’s trial, launches Nugevia ™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE)...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences to Participate in NobleCon21

Jupiter, Florida--(Newsfile Corp. - December 2, 2025) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based therapeutic...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease

Jupiter, Florida, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL ™ , a patented resveratrol-based therapeutic...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia ™ product line growth Jupiter, FL, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc (“JUNS”...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador

Partnership strengthens Nugevia ™ launch bringing clinical and scientific integrity to the fast-growing longevity space Jupiter, Florida, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Jupiter...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements

Targeting the Multi-Trillion Dollar Longevity Market Jupiter, Florida, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience

MND combines proprietary resveratrol-based platform and NovaSOL ® Curcumin to enhance cognitive performance and support neuroprotective health Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE)...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science

Transforming a promising molecule into a clinically viable therapeutic platform Jupiter, Florida, July 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"),...

JUNS : 1.1200 (-5.08%)
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

JUNS : 1.1200 (-5.08%)

Business Summary

Jupiter Neurosciences Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses...

See More

Key Turning Points

3rd Resistance Point 1.3298
2nd Resistance Point 1.2799
1st Resistance Point 1.1999
Last Price 1.1200
1st Support Level 1.0700
2nd Support Level 1.0201
3rd Support Level 0.9401

See More

52-Week High 19.5100
Fibonacci 61.8% 12.2520
Fibonacci 50% 10.0100
Fibonacci 38.2% 7.7680
Last Price 1.1200
52-Week Low 0.5100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar